Compare PBF & DNTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PBF | DNTH |
|---|---|---|
| Founded | 2008 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Integrated oil Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.3B | 5.9B |
| IPO Year | 2011 | 2018 |
| Metric | PBF | DNTH |
|---|---|---|
| Price | $66.11 | $88.96 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 15 | 18 |
| Target Price | $84.14 | ★ $139.25 |
| AVG Volume (30 Days) | ★ 2.7M | 936.2K |
| Earning Date | 10-29-2026 | 11-04-2026 |
| Dividend Yield | ★ 1.87% | N/A |
| EPS Growth | ★ 69.78 | N/A |
| EPS | ★ 21.82 | N/A |
| Revenue | ★ $24,508,200,000.00 | $2,036,000.00 |
| Revenue This Year | $46.18 | $36.90 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $3.20 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $25.62 | $34.29 |
| 52 Week High | $92.46 | $117.88 |
| Indicator | PBF | DNTH |
|---|---|---|
| Relative Strength Index (RSI) | 36.81 | 59.15 |
| Support Level | $58.42 | $81.16 |
| Resistance Level | $68.33 | $91.36 |
| Average True Range (ATR) | 4.66 | 4.01 |
| MACD | -1.49 | 1.79 |
| Stochastic Oscillator | 2.68 | 82.52 |
PBF Energy Inc is an independent petroleum refiner and supplier of unbranded transportation fuels, heating oil, petrochemical feedstocks, lubricants, and other petroleum products in the United States. The company owns refineries in Delaware, Ohio, New Jersey, California, and Louisiana. The Company operates in two reportable business segments: Refining and Logistics. The Company's oil refineries are all engaged in the refining of crude oil and other feedstocks into petroleum products and are aggregated into the Refining segment. PBFX operates logistics assets such as crude oil and refined products terminals, pipelines, and storage facilities. The Logistics segment consists solely of PBFX's operations.
Dianthus Therapeutics Inc. is a clinical-stage biotechnology company dedicated to developing potentially best-in-class therapies for patients with severe autoimmune diseases. The company operates as a single segment and has one reportable segment, focusing on creating next-generation treatments to revolutionize the management of severe autoimmune conditions. The team comprises experienced biotech and pharma executives. The pipeline includes the potential of Claseprubart, a next-generation complement therapeutic.